2022 Annual Meeting | Industry Therapeutic Update from Bristol Myers Squibb: ZEPOSIA: An Oral Option for Patients With Relapsing Forms of Multiple Sclerosis

Date Tuesday 04/05/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives

Discuss the prevalence of physical and cognitive symptoms in multiple sclerosis
Provide an overview of ZEPOSIA (indications and mechanism of action) and its robust data from 2 clinical trials with more than 2600 patients with Relapsing Multiple Sclerosis (RMS)
Review key efficacy and safety data from the ZEPOSIA pivotal Phase 3 clinical trials and the ongoing open-label extension trial

This event will be held in the Grand Hyatt Leonesa Ballroom I.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN.
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available 0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from Bristol Myers Squibb: ZEPOSIA: An Oral Option for Patients With Relapsing Forms of Multiple Sclerosis